Therapeutic expertise
Deep therapeutic specialization across five core disciplines
We concentrate our senior medical leaders and operational network where we can make the greatest impact: Dermatology, Internal Medicine, Neuroscience, Oncology and Ophthalmology.
View more
Immediate clinical immersion.
Speak scientist-to-scientist from day zero.
Clinical execution metrics that secure your trial.
+30
Years of clinical track record
+40
Countries with active footprint
+1,800
Completed clinical trials
88%
Team retention
Global presence designed for local agility
International scale, deep local roots
We have built our structure by integrating established clinical teams across key markets, rather than handing off trials to unknown third parties. Operating directly on the ground allows us to navigate local regulations, streamline ethics approvals and keep recruitment on track.
Australia
France
Hungary
Italy
Norway
Portugal
Sweden
United Kingdom
Belgium
Czech Republic
Finland
Germany
Israel
Netherlands
Poland
Spain
Switzerland
United States
Canada
Denmark
Updates to keep your trials
moving forward.
News
VERIGRAFT and TFS HealthScience partner on pivotal Phase II/III trial of personalized tissue-engineered vein for chronic venous insufficiency
Read news
News
Our 2025 sustainability year in review: the highlights
Read news
News
Europe's clinical development landscape: does the EU hold a busted flush or a full house?
Read news
News
Expanding the Frontiers of Neuroscience: TFS Strengthens Its Gene Therapy Portfolio in Neurodegenerative Diseases
Read news
Clinical operations & outsourcing FAQs.
What clinical outsourcing models does TFS provide?
We deliver three modular frameworks under a single contract: Strategic Resourcing, Functional Service Provider (FSP), and Full-Service Trials. This model elasticity allows you to scale clinical capacity fluidly as your pipeline demands, eliminating vendor handoffs.
What is the geographic footprint and reach of TFS?
Founded in Lund, Sweden, we operate as a global CRO with active regulatory and clinical reach across 40 countries. We combine comprehensive multi-region execution with specialized infrastructure and investigator networks across Europe and the Nordics.
How does TFS maintain clinical study continuity?
We maintain an industry-leading CRA turnover rate of 14%, significantly outperforming the 20% sector average. This team stability ensures consistent protocol knowledge, reduces management burden, and protects your data integrity.
Which therapeutic areas does TFS specialize in?
We concentrate our medical, clinical, and regulatory capabilities exclusively within five core areas: Dermatology, Internal Medicine, Neuroscience, Oncology, and Ophthalmology, backed by a track record of 1,800+ completed trials.